The National Institute for Health and Care Excellence has recommended sparsentan (Filspari, Vifor Pharma) for treating primary immunoglobulin A nephropathy in adults.
The recommendation reverses NICE’s February decision to reject NHS funding for the drug. The regulator had previously said available evidence did not demonstrate value for money.
The manufacturer provided additional analyses and agreed to a price discount, leading to the positive recommendation.
Clinical Benefits Demonstrated
Sparsentan reduces urine protein-to-creatinine ratio (UPCR) more effectively than standard treatment. The drug may also better maintain kidney function, NICE said.
In its final draft guidance, the regulator recommended sparsentan for IgAN patients with a urine protein excretion of 1.0 g/day or more, or a UPCR of 0.75 g/g or…